Coherus Oncology (CHRS) Short-term Investments (2017 - 2026)

Coherus Oncology (CHRS) has 9 years of Short-term Investments data on file, last reported at $51.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments changed N/A year-over-year to $51.8 million; the trailing twelve-month figure through Mar 2026 stood at $51.8 million (changed N/A YoY), and the FY2025 full-year result was $83.2 million, changed N/A from the prior year.
• Short-term Investments eased to $51.8 million in Q1 2026, from $83.2 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $128.1 million in Q4 2022 to a low of $14.9 million in Q4 2023.
• A 4-year average of $69.1 million and a median of $71.8 million in 2023 frame the typical range for Short-term Investments.
• Peak annual rise in Short-term Investments reached 88.41% in 2023, while the deepest fall reached 88.41% in 2023.
• Tracing CHRS's Short-term Investments over 4 years: stood at $128.1 million in 2022, then slumped by 88.41% to $14.9 million in 2023, then jumped by 460.32% to $83.2 million in 2025, then plunged by 37.76% to $51.8 million in 2026.
• Business Quant data shows CHRS's Short-term Investments at $51.8 million in Q1 2026, $83.2 million in Q4 2025, and $88.3 million in Q3 2025.